A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Twice Weekly for 21 Days.

Exclusion Criteria

• •Co-existing Condition:
• •Patients with the following symptoms or conditions are excluded:
• •Leukemia or lymphoma.
• •Current gastrointestinal bleeding by stool guaiac.
• •Extensive bone metastases or significant radiographic osteoporosis in patients with solid tumors.
• •Active heart disease such as uncontrolled angina, uncompensated congestive heart failure, or dysrhythmias requiring antiarrhythmics.
• •Acute intercurrent infection other than genital herpes.
• •Symptomatic or known central nervous system involvement (including brain metastases) unless stable and off therapy.
• •Concurrent Medication:
• •Excluded:
• •Other anticancer therapy.
• •Other investigational agents.
• •Patients with the following prior conditions are excluded:
• •History of acute or chronic gastrointestinal bleeding or inflammatory bowel disease.
• •History of myocardial infarction within past 6 months.
• •Prior Medication:
• •Excluded:
• •Anticancer therapy within the past 3 weeks (6 weeks for nitrosourea or mitomycin C).
• •Investigational agents within the past 4 weeks.